Advertisement

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

05:18 EDT 24th May 2013 | BioPortfolio

Summary

The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements on other clinical domains, such as quality of life, functional status.

Description

This clinical trial will be open label, flexible dose study of Divalproex ER vs Quetiapine for 6 weeks. Patients will be randomized to Divalproex ER vs Quetiapine outpatient / inpatient. The schedule of visits will include a screening, a baseline and 3 treatment visits / assessment. The End of Study/Early Termination visit will conclude the Trial. The safety follow-up visit will be scheduled only for the patients with unresolved Adverse Events detected prior or at the End of Study/Early Termination visit.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Alzheimer's Disease

Intervention

Divalproex ER, Quetiapine

Location

Cincinnati VA Hospital
Cincinnati
Ohio
United States
45220

Status

Terminated

Source

University of Cincinnati

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

Neuropil Threads

Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.

Alzheimer Vaccines

Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.

Aphasia, Primary Progressive

A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)

Amyloid Beta-protein Precursor

A precursor to the AMYLOID BETA-PROTEIN (beta/A4). Alterations in the expression of the amyloid beta-protein precursor (ABPP) gene, located on chromosome 21, plays a role in the development of the neuropathology common to both ALZHEIMER DISEASE and DOWN SYNDROME. ABPP is associated with the extensive extracellular matrix secreted by neuronal cells. Upon cleavage, this precursor produces three proteins of varying amino acid lengths: 695, 751, and 770. The beta/A4 (695 amino acids) or beta-amyloid protein is the principal component of the extracellular amyloid in senile plaques found in ALZHEIMER DISEASE; DOWN SYNDROME and, to a limited extent, in normal aging.

Down Syndrome

A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe MENTAL RETARDATION. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

Clinical Trials [ 648 Associated Clinical Trials listed on BioPortfolio]

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

The primary objective of this study is to compare the efficacy and tolerability of quetiapine versus divalproex extended-release administered in a rapid oral loading fashion in the treatme...

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

The primary hypothesis is that quetiapine will improve sleep in persons with Alzheimer's Disease (AD), with higher doses producing greater total sleep time and sleep efficiency.

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to tr...

CATIE-Alzheimer's Disease Trial

The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are ha...

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar...

PubMed Articles [ 6837 Associated PubMed Articles listed on BioPortfolio]

Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder.

Bipolar I disorder (BPD I) is a recurrent illness that affects 1% of the US population and constitutes a large economic burden. However, few studies have investigated the cost effectiveness of mainten...

Dibenzodiazepine Derivative Quetiapine- and Olanzapine-Induced Chronic Interstitial Nephritis.

The dibenzodiazepine derivative is a so-called "atypical" or second-generation antipsychotic that is widely regarded as one of the most effective drug treatments for schizophrenia and depression. Quet...

A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder.

Objective. To examine the longer-term efficacy of quetiapine monotherapy in bipolar depression in a preplanned pooling of data from the EMBOLDEN I and II studies. Methods. Patients (N = 584) with bipo...

Clinical and biomarker changes in Alzheimer's disease.

To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...

Clinical and biomarker changes in Alzheimer's disease.

To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...

More From BioPortfolio on "Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients"

Search BioPortfolio:
Advertisement
Advertisement